跳至主要内容
临床试验/NCT01647555
NCT01647555已完成不适用

Prospective Study About the Association of Radiotherapy and Cetuximab in the Treatment of Epidermoid Cancers, Locally Advanced, of the Head and Neck.

Centre Oscar Lambret7 个研究点 分布在 1 个国家目标入组 57 人开始时间: 2006年10月6日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
57
试验地点
7
主要终点
Skin toxicities

研究概览

简要总结

This study evaluates the skin toxicities in patients with epidermoid cancer, treated by Radiotherapy in association with Cetuximab.

详细描述

This prospective and multicentric study evaluates the skin toxicities in patients with locally Advanced head and neck epidermoid cancer, treated by Radiotherapy in association with Cetuximab.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age > 18 years
  • Epidermoid head and neck carcinoma locally advanced
  • Indication of Cetuximab and radiotherapy
  • Karnofsky >= 60
  • Patients participating to another compatible study could be included after consultation with the study director Patients could be beforehand treated for an other ORL cancer
  • The radiotherapy will be delivered for curative aim (minimal dose 66 Gy)

排除标准

  • other histology
  • Metastatic disease
  • Recurrent patients

研究组 & 干预措施

patient with epidermoid cancer

receiving Cetuximab and radiotherapy

干预措施: Cetuximab (Drug)

patient with epidermoid cancer

receiving Cetuximab and radiotherapy

干预措施: Radiotherapy (Radiation)

结局指标

主要结局

Skin toxicities

时间窗: until week 38

according to NCI-CTCAE version 3.0

次要结局

  • Healthcare and evolution of skin toxicities(until week 38)
  • tumoral efficacy(6 months after treatment)
  • Quality of life reporting(baseline, week 4, month 6)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (7)

Loading locations...

相似试验